In vivo biocompatibility evaluation of in situ-forming polyethylene glycol-collagen hydrogels in corneal defects

Yoon Hong Chun; Sun Kyoung Park; Eun Jeong Kim; Hyun Jong Lee; Hyewon Kim; Won Gun Koh; Gabriella Fernandes Cunha; David Myung; Kyung Sun Na

doi:10.1038/s41598-021-03270-3

In vivo biocompatibility evaluation of in situ-forming polyethylene glycol-collagen hydrogels in corneal defects

Yoon Hong Chun, Sun Kyoung Park, Eun Jeong Kim, Hyun Jong Lee, Hyewon Kim, Won Gun Koh, Gabriella Fernandes Cunha, David Myung, Kyung Sun Na

Department of Chemical and Biomolecular Engineering

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

The available treatment options include corneal transplantation for significant corneal defects and opacity. However, shortage of donor corneas and safety issues in performing corneal transplantation are the main limitations. Accordingly, we adopted the injectable in situ-forming hydrogels of collagen type I crosslinked via multifunctional polyethylene glycol (PEG)-N-hydroxysuccinimide (NHS) for treatment and evaluated in vivo biocompatibility. The New Zealand White rabbits (N = 20) were randomly grouped into the keratectomy-only and keratectomy with PEG-collagen hydrogel-treated groups. Samples were processed for immunohistochemical evaluation. In both clinical and histologic observations, epithelial cells were able to migrate and form multilayers over the PEG-collagen hydrogels at the site of the corneal stromal defect. There was no evidence of inflammatory or immunological reactions or increased IOP for PEG-collagen hydrogel-treated corneas during the four weeks of observation. Immunohistochemistry revealed the presence of α-smooth muscle actin (α-SMA) in the superior corneal stroma of the keratectomy-only group (indicative of fibrotic healing), whereas low stromal α-SMA expression was detected in the keratectomy with PEG-collagen hydrogel-treated group. Taken together, we suggest that PEG-collagen may be used as a safe and effective alternative in treating corneal defect in clinical setting.

Original language	English
Article number	23913
Journal	Scientific reports
Volume	11
Issue number	1
DOIs	https://doi.org/10.1038/s41598-021-03270-3
Publication status	Published - 2021 Dec

Bibliographical note

Funding Information:
This work was supported by a grant from the National Research Foundation of Korea (2019R1F1A1061421), a grant from the Catholic University Yeouido St. Mary’s Hospital in the program year of 2020 and a grant of translational R&D project through institute for Bio-Medical convergence, Incheon St. Mary’s Hospital, The Catholic University of Korea.

Publisher Copyright:
© 2021, The Author(s).

All Science Journal Classification (ASJC) codes

General

Access to Document

10.1038/s41598-021-03270-3

Cite this

@article{69cf9cb7bc014941b3564c49cc7ab286,

title = "In vivo biocompatibility evaluation of in situ-forming polyethylene glycol-collagen hydrogels in corneal defects",

abstract = "The available treatment options include corneal transplantation for significant corneal defects and opacity. However, shortage of donor corneas and safety issues in performing corneal transplantation are the main limitations. Accordingly, we adopted the injectable in situ-forming hydrogels of collagen type I crosslinked via multifunctional polyethylene glycol (PEG)-N-hydroxysuccinimide (NHS) for treatment and evaluated in vivo biocompatibility. The New Zealand White rabbits (N = 20) were randomly grouped into the keratectomy-only and keratectomy with PEG-collagen hydrogel-treated groups. Samples were processed for immunohistochemical evaluation. In both clinical and histologic observations, epithelial cells were able to migrate and form multilayers over the PEG-collagen hydrogels at the site of the corneal stromal defect. There was no evidence of inflammatory or immunological reactions or increased IOP for PEG-collagen hydrogel-treated corneas during the four weeks of observation. Immunohistochemistry revealed the presence of α-smooth muscle actin (α-SMA) in the superior corneal stroma of the keratectomy-only group (indicative of fibrotic healing), whereas low stromal α-SMA expression was detected in the keratectomy with PEG-collagen hydrogel-treated group. Taken together, we suggest that PEG-collagen may be used as a safe and effective alternative in treating corneal defect in clinical setting.",

author = "Chun, {Yoon Hong} and Park, {Sun Kyoung} and Kim, {Eun Jeong} and Lee, {Hyun Jong} and Hyewon Kim and Koh, {Won Gun} and Cunha, {Gabriella Fernandes} and David Myung and Na, {Kyung Sun}",

note = "Funding Information: This work was supported by a grant from the National Research Foundation of Korea (2019R1F1A1061421), a grant from the Catholic University Yeouido St. Mary{\textquoteright}s Hospital in the program year of 2020 and a grant of translational R&D project through institute for Bio-Medical convergence, Incheon St. Mary{\textquoteright}s Hospital, The Catholic University of Korea. Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1038/s41598-021-03270-3",

language = "English",

volume = "11",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - In vivo biocompatibility evaluation of in situ-forming polyethylene glycol-collagen hydrogels in corneal defects

AU - Chun, Yoon Hong

AU - Park, Sun Kyoung

AU - Kim, Eun Jeong

AU - Lee, Hyun Jong

AU - Kim, Hyewon

AU - Koh, Won Gun

AU - Cunha, Gabriella Fernandes

AU - Myung, David

AU - Na, Kyung Sun

N1 - Funding Information: This work was supported by a grant from the National Research Foundation of Korea (2019R1F1A1061421), a grant from the Catholic University Yeouido St. Mary’s Hospital in the program year of 2020 and a grant of translational R&D project through institute for Bio-Medical convergence, Incheon St. Mary’s Hospital, The Catholic University of Korea. Publisher Copyright: © 2021, The Author(s).

PY - 2021/12

Y1 - 2021/12

N2 - The available treatment options include corneal transplantation for significant corneal defects and opacity. However, shortage of donor corneas and safety issues in performing corneal transplantation are the main limitations. Accordingly, we adopted the injectable in situ-forming hydrogels of collagen type I crosslinked via multifunctional polyethylene glycol (PEG)-N-hydroxysuccinimide (NHS) for treatment and evaluated in vivo biocompatibility. The New Zealand White rabbits (N = 20) were randomly grouped into the keratectomy-only and keratectomy with PEG-collagen hydrogel-treated groups. Samples were processed for immunohistochemical evaluation. In both clinical and histologic observations, epithelial cells were able to migrate and form multilayers over the PEG-collagen hydrogels at the site of the corneal stromal defect. There was no evidence of inflammatory or immunological reactions or increased IOP for PEG-collagen hydrogel-treated corneas during the four weeks of observation. Immunohistochemistry revealed the presence of α-smooth muscle actin (α-SMA) in the superior corneal stroma of the keratectomy-only group (indicative of fibrotic healing), whereas low stromal α-SMA expression was detected in the keratectomy with PEG-collagen hydrogel-treated group. Taken together, we suggest that PEG-collagen may be used as a safe and effective alternative in treating corneal defect in clinical setting.

AB - The available treatment options include corneal transplantation for significant corneal defects and opacity. However, shortage of donor corneas and safety issues in performing corneal transplantation are the main limitations. Accordingly, we adopted the injectable in situ-forming hydrogels of collagen type I crosslinked via multifunctional polyethylene glycol (PEG)-N-hydroxysuccinimide (NHS) for treatment and evaluated in vivo biocompatibility. The New Zealand White rabbits (N = 20) were randomly grouped into the keratectomy-only and keratectomy with PEG-collagen hydrogel-treated groups. Samples were processed for immunohistochemical evaluation. In both clinical and histologic observations, epithelial cells were able to migrate and form multilayers over the PEG-collagen hydrogels at the site of the corneal stromal defect. There was no evidence of inflammatory or immunological reactions or increased IOP for PEG-collagen hydrogel-treated corneas during the four weeks of observation. Immunohistochemistry revealed the presence of α-smooth muscle actin (α-SMA) in the superior corneal stroma of the keratectomy-only group (indicative of fibrotic healing), whereas low stromal α-SMA expression was detected in the keratectomy with PEG-collagen hydrogel-treated group. Taken together, we suggest that PEG-collagen may be used as a safe and effective alternative in treating corneal defect in clinical setting.

UR - http://www.scopus.com/inward/record.url?scp=85121295314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121295314&partnerID=8YFLogxK

U2 - 10.1038/s41598-021-03270-3

DO - 10.1038/s41598-021-03270-3

M3 - Article

C2 - 34903788

AN - SCOPUS:85121295314

SN - 2045-2322

VL - 11

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 23913

ER -

In vivo biocompatibility evaluation of in situ-forming polyethylene glycol-collagen hydrogels in corneal defects

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this